Nan Fung Trinity HK Ltd. Acquires 9,842 Shares of Protagonist Therapeutics, Inc. $PTGX

Nan Fung Trinity HK Ltd. grew its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 7.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 144,892 shares of the company’s stock after purchasing an additional 9,842 shares during the quarter. Nan Fung Trinity HK Ltd. owned about 0.23% of Protagonist Therapeutics worth $9,625,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. BVF Inc. IL increased its holdings in Protagonist Therapeutics by 24.7% in the second quarter. BVF Inc. IL now owns 3,211,041 shares of the company’s stock worth $177,474,000 after purchasing an additional 636,026 shares in the last quarter. State Street Corp grew its position in shares of Protagonist Therapeutics by 18.5% during the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock worth $177,281,000 after buying an additional 500,924 shares during the period. Geode Capital Management LLC grew its position in shares of Protagonist Therapeutics by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,444,230 shares of the company’s stock worth $79,833,000 after buying an additional 20,671 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of Protagonist Therapeutics by 218.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,092,262 shares of the company’s stock valued at $60,369,000 after acquiring an additional 748,758 shares during the period. Finally, Commodore Capital LP acquired a new position in shares of Protagonist Therapeutics during the 2nd quarter valued at $59,415,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analysts Set New Price Targets

PTGX has been the subject of a number of research reports. BMO Capital Markets reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research note on Monday, October 13th. Johnson Rice set a $112.00 target price on Protagonist Therapeutics in a research report on Monday, October 13th. BTIG Research reiterated a “buy” rating and issued a $82.00 price target on shares of Protagonist Therapeutics in a report on Tuesday, October 28th. JPMorgan Chase & Co. raised their price objective on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, Wedbush upped their target price on Protagonist Therapeutics from $70.00 to $86.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $89.62.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 46,203 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $83.13, for a total value of $3,840,855.39. Following the completion of the sale, the chief financial officer directly owned 60,320 shares of the company’s stock, valued at approximately $5,014,401.60. This represents a 43.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $82.00, for a total transaction of $410,000.00. Following the transaction, the insider directly owned 84,115 shares in the company, valued at approximately $6,897,430. This represents a 5.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 165,167 shares of company stock worth $13,732,039 in the last quarter. 4.90% of the stock is currently owned by corporate insiders.

Protagonist Therapeutics Stock Up 2.6%

Shares of Protagonist Therapeutics stock opened at $81.80 on Friday. Protagonist Therapeutics, Inc. has a 52 week low of $33.70 and a 52 week high of $96.54. The business has a 50 day moving average price of $86.26 and a 200-day moving average price of $72.71. The company has a market cap of $5.11 billion, a PE ratio of 131.94 and a beta of 2.26.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03). Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%.The company had revenue of $4.71 million for the quarter, compared to the consensus estimate of $5.41 million. As a group, research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.